News

Physiomics Appoints of Anthony Clayden as part-time Head of Finance


TRY IT NOW

Sign up online today & collaborate

or click here to find out more

Physiomics Appoints of Anthony Clayden as part-time Head of Finance

 04/05/2016

Oxford, UK – The Company announces that Anthony Clayden, of Strategic Finance Director Limited, has been appointed Head of Finance to lead the financial management and provide company secretarial services with effect from 1 May 2016. This is not a board position, and Anthony is not being appointed a director or officer of Physiomics. At the same time the existing Financial Controller and Company Secretary, Liz King will step down from these duties but will remain available to support a transition.

Anthony has broad experience advising on strategy and managing the finance function in a variety of companies of differing size and complexity.  Anthony’s career has encompassed advising a number of businesses in the life sciences and healthcare sector. This includes over 6 years as Chief Financial Officer and Company Secretary of AIM quoted Futura Medical plc including preparation for and IPO on AIM and a series of placings during his tenure.

Paul Harper commented “We are pleased to announce the addition of Anthony to the senior management team with his AIM, sector and financial experience. On behalf of the Board I wish to thank Liz for her work at Physiomics and wish her well for the future.”

 

Enquiries:

Physiomics plc

Dr Jim Millen, CEO

+44 (0)1865 784 980

 

WH Ireland Limited (broker/nomad)

Katy Mitchell

+44 (0) 161 832 2174

 

About Physiomics plc

 04 May 2016: Oxford, UK – Physiomics is a computational systems biology services company applying simulations of cell behaviour to drug development to reduce the high attrition rates of clinical trials. 80-90 per cent of all clinical drug candidates fail to reach the market and estimates show that an overall ten per cent improvement in success rates could reduce the cost of one drug’s development by as much as $242 million, from the current estimate of around $800 million1.

Physiomics develops computational systems biology models to predict and understand cancer drug efficacy from pre-clinical research to clinical development. Physiomics has created detailed mathematical models incorporating the most important molecular events taking place during the human cell cycle and apoptosis processes. The company’s SystemCell® technology enables the simulation of populations of “virtual cells”. The company has also developed a “Virtual Tumour” model to simulate the effect of anti-cancer drugs on tumour growth. The models are used to optimise compound design and to design drug schedules and combination therapies.

Physiomics, based in Oxford, UK, was founded in 2001, and floated on AIM in 2004. For further information, please visit www.physiomics-plc.com

SystemCell® is a registered trademark of Physiomics plc

1Tufts Centre Impact Report 2002


CompanyPhysiomics plc
Company Websitehttp://www.physiomics-plc.com

© Catalyst Innovation Portal 2019